Evidence map›Paper›PMID 35609553›Full record

ArticleOncology2022

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade.

Jacqueline Niewolik, Marie Mikuteit, Anne Cossmann, Kai Vahldiek, Ralf Gutzmer, Frank Müller, Dominik Schröder, Stephanie Heinemann, Georg M N Behrens, Alexandra Dopfer-Jablonka and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Jacqueline NiewolikDepartment of Rheumatology and Immunology, Hanover Medical School, Hannover, Germany.
Marie MikuteitDepartment of Rheumatology and Immunology, Hanover Medical School, Hannover, Germany.
Anne CossmannDepartment of Rheumatology and Immunology, Hanover Medical School, Hannover, Germany.
Kai VahldiekInstitute for Information Engineering, Ostfalia University of Applied Sciences, Wolfenbüttel, Germany.
Ralf GutzmerDepartment of Dermatology, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany.
Frank MüllerDepartment of General Practice, University Medical Center Göttingen, Göttingen, Germany.
Dominik SchröderDepartment of General Practice, University Medical Center Göttingen, Göttingen, Germany.
Stephanie HeinemannDepartment of General Practice, University Medical Center Göttingen, Göttingen, Germany.
Georg M N BehrensDepartment of Rheumatology and Immunology, Hanover Medical School, Hannover, Germany.
Alexandra Dopfer-JablonkaDepartment of Rheumatology and Immunology, Hanover Medical School, Hannover, Germany.
Sandra SteffensDepartment of Rheumatology and Immunology, Hanover Medical School, Hannover, Germany.
Imke GrimmelmannDepartment of Dermatology and Allergy, Skin Cancer Center Hannover, Hanover Medical School, Hannover, Germany.
Medizinische Hochschule Hannover · DEUniversitätsmedizin Göttingen · DEJohannes Wesling Klinikum Minden · DEOstfalia University of Applied Sciences · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunogenicity of SARS-CoV-2 vaccines is modestly impaired in cancer patients due to a generally weakened immune system. Immune checkpoint inhibitors (ICI) are expected to enhance immune response. This has already been described to be the case in influenza vaccines, and first data about COVID-19 vaccines show a trend in this direction.

aimWe aimed to investigate the immune response of patients with melanoma under ICI therapy after COVID-19 vaccination. PATIENTS AND

methodsIn the Skin Cancer Center Hanover (Germany), we recruited 60 patients with advanced melanoma who either received ICI therapy during or before the vaccination period. Serological blood analysis was performed using quantitative ELISA for Anti-SARS-CoV-2 spike protein 1 IgG antibodies.

resultsWe did not observe an enhanced humoral immune response in patients under active or past ICI therapy after COVID-19 vaccination. Nevertheless, there is a tendency of higher antibody levels when ICI therapy was received within the last 6 months before vaccination. Subgroup analysis revealed that patients in our study population under ongoing targeted therapy during vaccination period had significantly higher median antibody levels than patients without any active antitumor treatment.

conclusionMelanoma patients under ICI therapy show comparable antibody response after SARS-CoV-2 vaccination to healthy health care professionals. This finding is independent of the timing of ICI therapy.

Indexed as

COVID-19MelanomaAntibodies, ViralCOVID-19 VaccinesHumansImmune Checkpoint InhibitorsSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesImmune Checkpoint InhibitorsAdvanced melanomaCOVID-19 vaccinationImmune checkpoint inhibitorsImmunogenicitySARS-CoV-2

Identifiers

PMID35609553
PMCPMC9393793
OpenAlexW4282938772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.